• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will China NDA Acceptance Change Henlius Stock's Narrative##

    Simply Wall St·09/18/2026 23:24:32
    Listen to the news
    • Shanghai Henlius Biotech reported that China's Center for Drug Evaluation accepted its NDA for HLX14, a 120 mg denosumab biosimilar vial, targeting cancer related bone complications and unresectable giant cell tumor of bone in patients with mature skeletons.
    • The HLX14 filing in China follows prior approvals of related products in the United States, Europe, the United Kingdom, and Canada, and points to a broader commercial push around denosumab biosimilars across oncology and osteoporosis treatment settings.
    • This development may shape Shanghai Henlius Biotech's investment narrative, given HLX14's NMPA NDA acceptance for cancer related bone disease.

    Scan how Shanghai Henlius Biotech fits into the wider healthcare opportunity set by reviewing our curated list of solid balance sheet and fundamentals (197 results) for potential peers with similar fundamentals.

    What Is Shanghai Henlius Biotech's Investment Narrative?

    To own Shanghai Henlius Biotech, you need to believe the group can turn a deep biologics pipeline into durable, cash generating franchises across oncology and chronic disease. The HLX14 denosumab biosimilar story goes right to that question. Global approvals already put the product in key markets. The fresh China NDA for the 120 mg vial targets cancer related bone disease, which ties directly to the firm’s oncology footprint and existing commercial infrastructure.

    The near term test is execution. That means converting IQVIA’s reported US$8.092b global denosumab market into share gains without eroding pricing too aggressively, managing the capital intensity of biologics manufacturing, and servicing a high debt load with earnings growth expected at 13.4% a year. Valuation remains rich on a 32x P/E versus local biotech peers, so the HLX14 ramp needs to justify that premium over time.

    Yet there is a quieter pressure point sitting in the background that could matter far more than the HLX14 headlines.

    There's only one way to know the right time to buy, sell or hold Shanghai Henlius Biotech. Head to Simply Wall St's company report for the latest analysis of Shanghai Henlius Biotech's Fair Value.

    SEHK:2696 1-Year Stock Price Chart
    SEHK:2696 1-Year Stock Price Chart

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that is truly your own.

    Looking For More Investment Ideas Beyond Shanghai Henlius Biotech?

    Once you have a view on Shanghai Henlius Biotech, it helps to compare that thesis against a wider bench of companies that share similar financial qualities or income profiles. The Simply Wall St Screener can surface that broader opportunity set in a few clicks.

    • If capital preservation is a priority, you can start with resilient balance sheets and low risk profiles by reviewing the 227 resilient stocks with low risk scores that match your comfort level.
    • For investors who care most about value, you can scan for stronger fundamentals at what could be appealing prices through our curated 179 high quality undervalued stocks.
    • If income matters to your plan, you can focus on consistent cash returns by checking out the 156 dividend fortresses that combine yield with stability.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.